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Summary Survival data on a population-based series of bone, soft tissue and visceral sarcomas diagnosed in
the North West of England between 1982-84 and subjected to histopathological peer review are presented.
Five-year crude survival for all cases was 34%. Survival in males and females did not differ significantly
(P = 0.6, 5-year survival 32% vs 36%) but was markedly worse for patients diagnosed over the median age of
60 years, even when allowance was made for underlying mortality (P = 0.03, 34% vs 44%). Five-year survival
rates for the major site groups were: bone 44%; soft tissues of head, neck and trunk 36%; soft tissues of
extremities 35%; female genital tract 35%; retroperitoneum 15%; gastro-intestinal tract 13%. Analysis by the
major histological types revealed the following survival rates: leiomyosarcoma - female genital tract 25%,
gastro-intestinal tract 14%, non-visceral soft tissue 21%; malignant fibrous histiocytoma of soft tissue 29%;
liposarcoma 52%; osteosarcoma of bone 46%; and chondrosarcoma of bone 50%.
Most published data on survival in sarcomas relates to
selected patients referred to specialist treatment centres (Mar-
khede et al., 1982; Bramwell et al., 1985; 1989; Collin et al.,
1987; Stotter et al., 1990; El-Jabbour et al., 1990). Survival
data from other, more broadly-based groups, have not relied
upon centrally reviewed histological diagnoses for all the
cases included (Tucker & Fraumeni, 1982; Fraumeni &
Boice, 1982). Exceptions to these generalisations are certain
childhood series which relate to defined populations and
include special histopathological review of all cases ascer-
tained (Craft et al., 1987; Birch et al., 1988) and a recently
reported population-based study of malignant fibrous his-
tiocytoma from the southern health care region of Sweden
(Rooser et al., 1991).
Soft tissue and bone sarcomas are rare tumours and,
because of the wide variety of sub-types and sites of tumour
which are seen, estimation of survival is difficult. Added to
this is the observation that histopathological review often
results in change in diagnosis of sub-type and may even
result in certain tumours being redesignated as non-sarcomas
(Presant et al., 1986; Alvegard & Berg, 1989, El-Jabbour et
al., 1990; Agnarsson et al., 1991).
The cases reported here, ascertained over a 3-year period
from a defined geographical region, have been subjected to
histopathological review by a panel of five pathologists.
Follow-up to ascertain vital status over a 5 year period was
almost complete and this paper reports the patterns of sur-
vival seen.
Methods
All cases of sarcomas notified to the North Western Regional
Cancer Registry for the period 1982-1984 together with
those cases, which on individual scrutiny appeared to have
been considered as possible sarcomas, were ascertained for
the study. A more detailed description of ascertainment is
given elsewhere (Hartley et al., 1991). Cases included for
histopathological review were those malignant soft tissue
tumours (including visceral tumours) listed by Enzinger and
Weiss (1988), together with osteosarcoma, chondrosarcoma,
Ewing's tumour and other primary bone sarcomas. Certain
other tumours where sarcoma is sometimes considered as a
differential diagnosis, or where degree of malignancy is often
uncertain, were also included, but mesothelial tumours and
certain mixed tumours e.g. carcinosarcoma and Mullerian
mixed tumour were excluded.
Slides from representative blocks were stained with
haematoxylin and eosin and circulated to each of the five
panel pathologists together with a brief clinical summary for
each case, where available. Individual diagnoses were
recorded by members and circulated to the rest of the panel.
In cases of disagreement, final (panel) diagnoses were arrived
at by consensus after further scrutiny of slides at meetings
and, if necessary, after the application of special stains.
Details of the review method are given elsewhere (Harris et
al., 1991). Because of the variability in the amount and
quality of the material received, grade of malignancy could
not be specified, nor was information about tumour stage or
the presence of metastatic disease available for the study.
Final diagnoses were coded using ICD-0 (WHO, 1976).
Cases were also coded for vital status and date of death, if
appropriate. Surviving patients were 'flagged' on the
National Health Service Central Register (NHSCR) for date
of death.
This study of survival is based largely upon those cases for
which a final (panel) diagnosis of sarcoma was agreed. Addi-
tional analyses were carried out to take into consideration
those cases originally registered as sarcomas on clinical
grounds and those for whom material could not be obtained
for review, or for whom a diagnosis could not be made.
Survival was measured from date of original diagnosis. For
surviving cases 'flagged' at NHSCR the date of last follow up
was taken as 30th June 1990 thus giving a minimum of 5
years follow-up for all cases. Kaplan-Meier survival curves
(referred to as crude survival curves) were calculated for all
cases and by sex and age group for all diagnoses combined,
for certain diagnostic sub-types and for each major site
(Kaplan & Meier, 1958). 95% confidence intervals were cal-
culated for 5-year survival rates and survival curves were
compared using the log rank test (Peto et al., 1977). For
examination of survival by age at diagnosis groups were
sub-divided at median age, or at an approximation to it, in
order to give two groups of more or less equal size for
comparison.
In order to take account of mortality due to causes other
than sarcoma, expected survival curves were calculated from
annual sex- and 5-year age group specific mortality rates for
all causes of death in the North Western Regional Health
Authority (NWRHA) area during the years 1982-1990.
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Observed survival curves were divided by those expected to
obtain relative survival curves which were compared using an
additive model for the hazards (Buckley, 1984). The com-
puter package Epilog Plus, version 2, was used for all the
statistical analyses (1987).
Results
Out of a total of 59,784 cancer registrations for the North
Western Region for the years 1982-84, 450 cases were
registered as sarcomas and 313 of these were confirmed as
such on panel review. From the additional 18 cases selected
because of uncertain malignancy or because of mention of
sarcoma as a differential diagnosis or cause of death on the
registration form, two were confirmed as sarcomas by the
panel. For this analysis five cases were excluded from the 315
reviewed cases with a final diagnosis of sarcoma: on further
scrutiny four were found to have been originally diagnosed
outside the NWRHA area and one case had diagnosis date
incorrectly notified. Distribution by histological type for the
310 cases included in the survival analyses are shown in
Table I.
An additional 38 cases (Table II) were included in some
analyses. These included 19 clinically-diagnosed cases; 13
cases where no material was received or could be obtained
from the fixed material sent; and six cases where histological
material was received but no diagnosis could be made by the
panel.
All surviving cases, except one, were successfully 'flagged'
on the NHSCR so that current vital status was available. For
the non-flagged case the date last seen was abstracted from
hospital notes and was taken as the date of the last follow
up.
Crude survival curves for all sarcomas and for certain
subgroups are shown in Figures 1-8 and a summary of
crude and relative survival for the major sites and his-
tological groups is given in Table III. Survival rates quoted
are those at 5 years and the P values are those comparing the
entire survival curves. Comments in general refer to reviewed
cases except where any striking differences emerged when
non-reviewed cases were taken into consideration, and to
crude survival, rather than relative survival, other than where
Table I Cases included by histological type 1982-84
Histology Male Female Total
Soft tissue sarcomas
Leiomyosarcoma
Gastrointestinal tract 9 5 14
Female genital tract 0 20 20
Other sites 14 23 37
Malignant fibrous histiocytoma 25 24 49
Sarcoma NOS 21 13 34
Liposarcoma 7 14 21
Malignant peripheral nerve
sheath tumour 7 5 12
Rhabdomyosarcoma 7 4 11
Haemangiosarcoma 6 4 10
Endometrial stromal sarcoma 0 9 9
Synovial sarcoma 0 5 5
Other specified soft tissue
sarcoma 13 18 31
Total soft tissue sarcoma 109 144 253
Bone tumours
Osteosarcoma 14 10 24
Chondrosarcoma 15 7 22
Ewing's tumour 3 4 7
Malignant fibrous histiocytoma 1 0 1
Haemangiosarcoma 1 0 1
Chordoma 1 0 1
Sarcoma NOS 0 1 1
Total bone tumours 35 22 57
Total sarcomas 144 166 310
Table II Original registered diagnosis for other cases included in
survival analysis
1982-84
Male Female Total
Clinical diagnosis
Soft tissue
Sarcoma NOS 5 3 8
Bone
Osteosarcoma 8 1 9
Sarcoma NOS 0 1 1
Chordoma 0 1 1
No material received/no diagnosis made
Soft tissue
Sarcoma NOS 2 1 3
Liposarcoma 3 0 3
Synovial sarcoma 0 2 2
Leiomyosarcoma 0 2 2
Kaposi's sarcoma 1 0 1
Haemangiosarcoma 1 0 1
Bone
Osteosarcoma 1 2 3
Chondrosarcoma 1 1 2
Chordoma 1 0 1
Sarcoma NOS 1 0 1
Overall Total 24 14 38
age was a consideration. Where ages other than median ages
have been used for analysis, these have also been shown in
Table III.
The 5-year survival rate for all reviewed sarcoma patients
was 34% and there was no statistically significant difference
in survival between males and females (P = 0.6, males 32%,
females 36%) (Figure 1). Survival, however, was significantly
worse for patients diagnosed over the median age of 60 years
(P = <0.0001, < 60 yrs 43%, > 60 yrs 24%) (Figure 2) and
this difference persisted when the rates were corrected for
underlying mortality (P = 0.03, relative survival < 60 yrs
44%, > 60 yrs 34%).
Stratification by site of tumour (Figure 3) revealed a higher
rate of survival in patients with bone tumours (44%) than for
those with sarcomas of female genital tract (35%), of non-
visceral soft tissue and miscellaneous sites (32%) and of
gastro-intestinal tract (13%). Numbers in the last category
were, however, very small and the overall difference in sur-
vival by site was only of borderline significance (P= 0.08).
The differences were less marked when relative survival was
considered (P = 0.2). The survival of males and females with
tumours of non-visceral soft tissue and miscellaneous sites
was very similar (P = 0.4). Two of the five female patients
with a tumour of the gastro-intestinal tract survived 5 years
but all of the ten male patients died within 3 years
(P = 0.08). Male patients with bone sarcomas had a mar-
ginally better survival than female patients but this difference
did not attain statistical significance (P = 0.3).
Further sub-division of patients with tumours of non-
visceral soft tissue into those with tumours of head, neck and
trunk; extremities or retroperitoneum showed a statistically
significant difference in survival between these sites (P=
0.03). This finding was related mainly to the very poor
survival of patients with retroperitoneal tumours (5-year sur-
vival = 15%). There were no significant differences in sur-
vival by sex of patient for these three site sub-groups.
Stratification by age within the major sites indicated that
crude survival appeared consistently better for the younger
patients but the difference only attained statistical
significance for non-visceral soft tissue combined with miscel-
laneous sites and for female genital tract. Five-year crude
survival for the former group was 38% in patients aged
under 65 years at diagnosis compared with 25% for those
aged 65 years and over (P = 0.04). Difference in survival bySURVIVAL IN PATIENTS WITH SARCOMAS 687
Table III Crude and relative five-year survival for reviewed bone and soft tissue sarcomas by diagnostic group and
site
Diagnostic
group/site
All sarcomas
Males
Females
Aged<60
Aged >60
No. in
group
310
144
166
155
155
Median age
at diagnosis
(yrs)
59.5 (60)'
61
57
39
71
Crude Survival
% survival
at 5 years
34
32
36
43
24
95% CI
29-39
24-40
29-43
35-51
17-31
Relative Survival
% survival
at 5 years 95%
40 34-
38 29-
41 32-
44 36-
34 25-
Soft tissue sarcomas
Non-visceral soft
tissue and
miscellaneous sites
Males
Females
Aged <65
Aged 65
Head, neck & trunk
Males
Females
Aged<60
Aged > 60
Extremities
Males
Females
Aged<70
Aged > 70
Retroperitoneum
Female genital tract
Aged< 55
Aged 55
Gastro-intestinal
tract
Leiomyosarcoma
Non-visceral soft
tissue
Female genital tract
Gastro-intestinal
tract
MFH of soft tissue
Sarcoma NOS of non-
visceral soft tissue
Liposarcoma
All bone sarcomas
Males
Females
Aged<35
Aged> 35
Osteosarcoma of bone
Chondrosarcoma of
bone
207 62 (65)
99
108
117
90
87
37
50
43
44
82
42
40
45
37
27
31
16
15
15
33
20
14
48
28
21
57
35
22
29
28
24
22
32 26-38
62 28
61 36
50 38
73 25
61 (60) 36
62 35
54 36
34 42
71 30
67.5 (70) 35
66.5 31
70.5 40
55 44
74 24
58 (60) 15
54 (55) 35
46.5 56
66 13
67 (70) 13
70 (70)
56 (55)
69 (70)
70.5 (70)
61.5 (60)
59 (60)
33 (35)
33
32.5
16
69
18 (20,30b)
63 (65)
21
25
14
29
32
19-37
27-45
29-47
16-34
26-46
20-51
23-49
27-57
16-43
25-46
17-45
24-55
30-59
10-39
1 -28
18-52
32-80
0-30
0-30
6-36
6-44
0-32
16-42
15-49
52 31-73
44
51
32
52
36
46
50
31-57
35-67
12-52
34-70
18-54
26-66
29-71
39 31-47
35
43
40
37
42
43
41
43
41
45
39
51
49
39
17
38
58
15
17
24-46
32-54
31-49
23-51
30-54
24-62
26-56
28-58
22-59
32-58
22-57
31 -71
33-64
15-62
2-32
20-56
33-83
0-34
0-39
27 8-46
27 6-48
19 0-43
39 22-56
38 18-58
61 36-86
49
59
35
52
46
50
58
35-63
40-78
14-56
34-70
23-69
28-72
34-82
aBoundary used for comparison of survival by age group. bIncluding non-reviewed cases.
age for tumours of female genital tract was even more strik-
ing (P = 0.005, < 55 yrs 56%, aged 55 + yrs 13%). Patients
aged less than 35 years at diagnosis of their bone tumours
had a higher 5-year survival rate than those over 35 years
(52% vs 36%) but the difference was not significant
(P = 0.1). Although the age differential in survival was main-
tained for each major site group when correction for under-
lying mortality was made, the only statistically significant
difference remaining was that for tumours of female genital
tract (P = 0.01).
Survival was also measured for certain diagnostic groups
where numbers permitted, i.e. leiomyosarcoma, malignant
fibrous histiocytoma (MFH), liposarcoma, osteosarcoma and
chondrosarcoma.
Because a large proportion (38/71) of leiomyosarcomas in
the series were of visceral sites, i.e. female genital tract and
gastro-intestinal tract, and because leiomyosarcoma also
formed the largest single group of tumours within these sites,
separate survival curves were constructed to take site into
account (Figure 4). Five-year survival was uniformly poor
ranging from 14% for leiomyosarcoma of gastro-intestinal
tract to 25% for that of female genital tract. Numbers in
each sub-group, however, were small, and there was no
significant difference overall (P = 0.6). Analyses by age and
sex within each sub-group were generally inconclusive apart
from a better relative survival for patients with leiomyosar-
coma of female genital tract diagnosed under the median age
of 55 years (P = 0.05, relative survival 45% vs 10%).
Survival in MFH was also low with only 29% of cases
alive after 5 years, but survival in those aged under 70 years
at diagnosis was strikingly better than in those aged 70 years
and over (Figure 5), even when adjusted for underlying
mortality (P=0.01, relative survival overall 39%, <70yrs
54%, 70 + yrs 20%).
Patients with liposarcoma had a 52% survival rate at 5
years and, as with MFH, there was a marked difference in
survival by age group with older patients having a poorer
prognosis (Figure 6). Overall relative survival at 5 years was
CI
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Figure 4 Survival curves for patients with leiomyosarcoma by
site of tumour.
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Figure 5 Survival curves for patients with malignant fibrous
histiocytoma of soft tissue by age at diagnosis.
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osteosarcoma and chondrosarcoma, were very similar with
the greatest mortality in both occurring in the first 2-3 years.
There was no significant difference for either sub-type by sex
of patient but markedly different patterns emerged when the
data were stratified by age at diagnosis, possibly because of
the wide difference in the median age at diagnosis in the two
groups. Osteosarcoma patients diagnosed under age 20 years
had more than twice the 5-year survival rate than those
diagnosed over this age (P= 0.01, 62% vs 27%) (Figure 7), a
--------------I-ltinerence which was also apparent in relative survival rates
------------- (P= 0.02, 62% vs 34%). For patients with chondrosarcoma
the difference in survival by age was not significant, but the
numbers studied were small.
I I I__ Even more striking differences in survival by age were seen
I 1 2 3 4 5 for osteosarcoma when non-reviewed as well as reviewed
Years cases were taken into consideration. Most of the non-
reviewed cases of osteosarcoma (8/12) occurred in elderly
Survival curves for all sarcoma patients by site of individuals in whom diagnosis was based upon clinical
criteria only. Inclusion of these in the analysis resulted in a
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Figure 8 Survival curves for patients with chondrosarcoma of
bone by age at diagnosis.
median age at diagnosis for the group as a whole (29 the study (Harris et al., 1991). Inclusion of these ineligible
and a much greater survival differential with 56% cases in any non-reviewed series may bias survival data.
,urvival at 5 years for those aged less than 30 years at Many studies have investigated prognostic variables for
sis and 11% for those aged 30 years and over survival in sarcomas. Most of these have either concentrated
0004). Relative survival was 56% vs 15% (P = 0.002). upon features of the tumour itself, i.e. histological grade,
size, depth, degree of necrosis etc. (Trojani et al., 1984;
Rooser et al., 1988; Ueda et al., 1988; Mandard et al., 1989)
[ion or on various treatment modalities (Markhede et al., 1982;
Bramwell et al., 1985; Suit et al., 1985). In addition, most of
tl in sarcoma patients is difficult to assess reliably these observations have been made on hospital-based or on
of the rarity of such tumours, their differing topo- selected sub-sets of population-based series.
-al sites, the wide range of histological types seen and Grading of tumours was not part of the protocol for this
fculty of assessing degree of malignancy in certain study so each group of sarcomas considered here is very
As a result of these factors, most published series mixed with respect to malignant potential. Nor was inform-
have included special pathology review have reported ation on the presence ofmetastatic disease generally available
certain proportion of cases have been eliminated at the time of case ascertainment. Hence the results represent
ient to re-classification as malignant tumours other a broad generalisation in terms of survival. In addition,
Lrcomas, connective tissue tumours of borderline or because of the small numbers of some histological types the
vin malignant potential, benign tumours or non- power of the study to detect differences in survival within
tic conditions (Presant et al., 1986; AlvegArd & Berg, and between groups was low in some cases.
1-Jabbour et al., 1990, Agnarsson et al., 1991). This is Overall 5-year survival for the patients with reviewed histo-
e case in the present series where a non-sarcoma logy entered in this series was 34%. In general, survival for
is was made in 22% of the cases originally entered in bone sarcomas was marginally better than that for soft tissue
tumours of any specified site i.e. bone 44%; female genital
tract 35%; soft tissue sites 32%;and gastro-intestinal tract
13%, but this difference may be related to the younger age at
nn .diagnosis of the bone tumour natients. The vrognosis for all
0.75
the major histological groups of soft tissue tumours, other
than for liposarcoma, was below the average for the entire
series. The relatively good survival for liposarcoma probably
reflects the inclusion of histological sub-types which are
recognised to behave in a low grade manner, i.e. well
differentiated and myxoid liposarcoma (Enzinger & Weiss,
1988).
Comparison with the population-based series of MFH
0.50 reported from Sweden (Rooser et al., 1991) indicated that
--------5 survival in our series was much poorer (29% vs 72%) and
L----- that the very marked survival differential between younger
- - - and older patients was not apparent in the Swedish series.
0.25---------------------------- Possible reasons for these discrepancies could lie in the 0e25 - differing definitions of younger and older age groups for the
Age 019 (N -13) two series, the higher median age at diagnosis in our series
----- Age 20+ (N 11) and the different proportions of histological sub-types within
the two groups. No direct comparisons of survival by histo-
0.0 1 3 4 5 logical type with any other series is possible because of
0Y1
2
rs differences in ascertainment of patients and in the extent of
Years centralised histopathology review.
7 Survival curves for patients with osteosarcoma of bone Prognostic variables covered by this study other than site
at diagnosis. and histological type were age and sex. Although females
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overall had a slightly better 5-year survival rate than males
(36% vs 32%), the difference was reversed for bone tumour
patients (51% vs 32%) but neither difference was statistically
significant. Better survival in female soft tissue sarcoma
patients has been noted by R66ser et al. (1988), Ueda et al.
(1988) and El-Jabbour et al. (1990), but no difference was
apparent in other series (Bramwell et al., 1985; Collin et al.,
1987).
The most consistent finding in these analyses was the
better prognosis for younger patients as reported by other
investigators (Bramwell et al., 1985; Collin et al., 1987; El-
Jabbour et al., 1990). Five year relative survival for patients
who were under the median age at diagnosis of 60 years was
44% as opposed to 34% in those aged 60 years and over
(P = 0.03). This survival differential was particularly striking
for sarcomas (including leiomyosarcoma) of female genital
tract, for MFH, osteosarcoma of bone and sarcoma NOS.
The wide divergence in survival between younger and older
patients with osteosarcoma when all non-reviewed cases are
taken into consideration is explained largely by the inclusion
of a group of elderly patients, most of them male and with
tumours associated with Paget's disease of bone in whom
survival was particularly poor.
One of the encouraging results to emerge from the study
was the high level of survival in children and young adults
with osteosarcoma (62% at 5 years for patients aged under
20 years at diagnosis), a feature noted by Birch et al. (1988)
for younger children registered with the Manchester Child-
ren's Tumour Registry, some of whom were also entered in
this study. The improved level of survival for osteosarcoma
in young people may be a reflection of the increasing trend
towards the centralisation of treatment of childhood cancer
in Britain which has been shown to have a favourable effect
on survival for the period 1977-84 (Stiller, 1988). Most
children and young adults in the North West region are
treated centrally by consultants who are members of the
United Kingdom Children's Cancer Study Group.
No analysis in general of survival by treatment centre was
possible for patients in this series. Although a high propor-
tion of patients was seen at the Christie Hospital and Holt
Radium Institute, the major cancer treatment centre in the
North Western region, no consistent information was
available on reason for referral, i.e. for initial diagnosis,
primary treatment, treatment of recurrence or palliation. Nor
were treatment details available. Hence no comment can be
made on how the survival patterns described here relate to
primary treatment or adjuvant therapies.
The overall survival rates presented here may seem depres-
singly poor, especially those for the soft tissue tumours. It is
important to bear in mind, however, that this series encom-
passes all cases from the North Western region, including
those who were diagnosed at post mortem or died before
treatment could be instituted, those who were considered too
old or ill for active treatment, and those not referred to a
primary treatment centre or referred only at the time of
development ofmetastatic disease. Hence, although the study
looked at a limited range of prognostic variables, i.e. histo-
logical type, site, age and sex, because it was truly
population-based and included peer-review of histology, the
results give a realistic assessment of overall survival for
different types of sarcomas.
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